drugset / Trial / NCT01786096
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).
Timeline
- Start
- 2013-02
- Primary completion
- 2017-05-30
- Completion
- 2017-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | denintuzumab mafodotin | Unknown | 0.3 mg/kg | Intravenous |
| Subject | denintuzumab mafodotin | Unknown | 6 mg/kg | Intravenous |